The investigational Bruton's tyrosine kinase inhibitor fenebrutinib reduced annualized relapse rates versus teriflunomide ...

The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

William Blair analyst Myles Minter downgraded Biohaven (BHVN) to Market Perform from Outperform. The announcement of a CRL for troriluzole in spinocerebellar ataxia halts not only a near-term source ...

・Biohaven was seeking approval for its drug Vyglxia in the treatment of Spinocerebellar ataxia. ・The company is in the process of formally requesting a meeting as soon as possible to determine the ...

UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...

The International Society for Vascular Behavioral and Cognitive Disorders updated criteria for diagnosing vascular cognitive impairment and dementia. (JAMA Neurology) Paramagnetic rim lesions improved ...

Mast cell activation syndrome is a condition that causes mast cells to release an inappropriate amount of chemicals into your body. This causes allergy symptoms and a wide range of other symptoms.